caa a22 4500 47705806X CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960101xx s 000 0 eng 10.1007/BF00226327 doi (NATIONALLICENCE)springer-10.1007/BF00226327 Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline [Elektronische Daten] [A. Korn, B. Wagner, J. Dingemanse, E. Moritz] Objective: The objectives of this double-blind study were to assess the tolerability and i.v. tyramine pressor response during combined treatment with moclobemide and selegiline. Subjects: Two parallel groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.d. for 14 days. On Day 7, selegiline or moclobemide was added to the other treatment. IV tyramine pressor tests were conducted at baseline and at steady state during mono- and combined treatment. Results: Treatment with moclobemide and selegiline alone was well tolerated, whereas combined treatment led to a slight increase in adverse events. Tyramine pressor sensitivity during moclobemide, selegiline and moclobemide + selegiline treatment was enhanced, on average, by 2.4-, 1.3- and 8.4-times, respectively. Conclusion: Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy. Springer-Verlag, 1996 Moclobemide nationallicence Selegiline nationallicence interaction nationallicence pharmacodyamics nationallicence tyramine nationallicence Korn A. Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria aut Wagner B. Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria aut Dingemanse J. Department of Clinical Pharmacology, Hoffmann-La Roche Ltd., CH-4002, Basel, Switzerland aut Moritz E. Department of Clinical Pharmacology, Hoffmann-La Roche Ltd., CH-4002, Basel, Switzerland aut European Journal of Clinical Pharmacology Springer-Verlag 49/4(1996-01-01), 273-278 0031-6970 49:4<273 1996 49 228 https://doi.org/10.1007/BF00226327 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00226327 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Korn A. Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria aut NATIONALLICENCE 700 1- Wagner B. Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria aut NATIONALLICENCE 700 1- Dingemanse J. Department of Clinical Pharmacology, Hoffmann-La Roche Ltd., CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Moritz E. Department of Clinical Pharmacology, Hoffmann-La Roche Ltd., CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/4(1996-01-01), 273-278 0031-6970 49:4<273 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer